Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With <scp>HCC</scp> Treated With Durvalumab Plus Tremelimumab
LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.
Authors
- Kazunari Tanaka (ORCID: https://orcid.org/0000-0001-9811-2665)
- Yuki Kanayama (ORCID: https://orcid.org/0000-0002-8639-5212)
- Tomomitsu Matono
- Hidenao Noritake (ORCID: https://orcid.org/0000-0003-3649-5335)
- Kazuhito Kawata (ORCID: https://orcid.org/0000-0002-4986-8578)
- Kazuya Kariyama (ORCID: https://orcid.org/0000-0003-3996-7502)
- Hideyuki Tamai (ORCID: https://orcid.org/0000-0003-4511-4573)
- Yoichi Nakamura (ORCID: https://orcid.org/0000-0001-5958-5304)
- Kunihiko Tsuji (ORCID: https://orcid.org/0009-0007-4152-9364)
- Takuya Nagano (ORCID: https://orcid.org/0000-0003-1043-8033)
- Ei Itobayashi (ORCID: https://orcid.org/0000-0003-0475-2819)
- S KIM
- TOSHIFUMI TADA
- Hiroko Iijima (ORCID: https://orcid.org/0000-0002-5841-8827)
- Hisashi Kosaka (ORCID: https://orcid.org/0000-0002-2926-9973)
- Kazuto Tajiri (ORCID: https://orcid.org/0000-0002-2373-8601)
- Akemi Tsutsui (ORCID: https://orcid.org/0000-0003-2978-2723)
- Satoaki Nakamura (ORCID: https://orcid.org/0000-0001-5721-3734)
- Yuichi Koshiyama (ORCID: https://orcid.org/0009-0006-1247-1215)
- Fujimasa Tada (ORCID: https://orcid.org/0009-0007-3964-5876)
- Michitaka Imai (ORCID: https://orcid.org/0000-0001-6448-6036)
- Kosuke Matsui (ORCID: https://orcid.org/0000-0002-7274-0177)
- Masaki Kaibori
- Hideko Ohama
- Chikara Ogawa
- Y. Hiasa
- Joji Tani
- Jumpei Okamura
- Takashi Kumada
- Toru Ishikawa
- Taeang Arai
- Yoshihide Ueda
- Yutaka Yata
- the RELPEC Group and HCC 48 Group
- Tomomi Okubo
- Masashi Hirooka
- Tomoko Aoki
- Takumi Fukumoto
- Masanori Atsukawa
- Kazuhiro Nouso
- Hiroki Nishikawa
- Osamu Yoshida
- Hidekatsu Kuroda
- Shohei Komatsu
- Takeshi Hatanaka
- Asahiro Morishita
- Hironori Tanaka
- Koichi Takaguchi
- Atsushi Hiraoka
- Hidenori Toyoda
- Hironori Ochi
- Takashi Nishimura
- Atsushi Naganuma
- Takanori Matsuura
- Satoru Kakizaki
- Masatoshi Kudo
Institutions
- Hiroshima University (JP)
- Kansai Medical University (JP)
- Iwate Medical University (JP)
- Kagawa University (JP)
- Hamamatsu University School of Medicine (JP)
- Wakayama Rosai Hospital (JP)
- Niigata Cancer Center Hospital (JP)
- Takamatsu Red Cross Hospital (JP)
- Saiseikai Niigata Daini Hospital (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Matsuyama Red Cross Hospital (JP)
- Ogaki Municipal Hospital (JP)
- Himeji Medical Center (JP)
- Hanwa Memorial Hospital (JP)
- Gunma Saiseikai Maebashi Hospital (JP)
- Himeji Red Cross Hospital (JP)
- Kagawa University Hospital (JP)
- Teine Keijinkai Hospital (JP)
- Asahi General Hospital (JP)
- Toyama University Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- Edogawa Hospital (JP)
- Kobe Asahi Hospital (JP)
- Kagawa Prefectural Central Hospital (JP)
- Takarazuka City Hospital (JP)
- Ehime University (JP)
- Gifu Kyoritsu University (JP)
- Kobe University (JP)
- Nippon Medical School (JP)
- Hyogo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Liver International
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1111/liv.70570
- Citations
- 1
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 24.20